Form 4: Vor Biopharma's Chief Medical Officer, Eyal C. Attar, Reports Stock Sale

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reported selling 10,334 shares of common stock at $1.25 per share on December 27, 2024, according to a Form 4 filing.

Summary

• On December 27, 2024, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., sold 10,334 shares of the company's common stock.
• The sale was executed at a price of $1.25 per share.
• Following the transaction, Attar directly owns 81,439 shares of Vor Biopharma Inc.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of a stock sale under a pre-arranged trading plan. It doesn't necessarily indicate a negative outlook on the company.

Industry Context

This filing is a routine disclosure of insider trading activity. It's important to monitor such filings to understand the sentiment of company executives regarding the company's stock. However, sales under 10b5-1 plans are often pre-scheduled and may not reflect current sentiment.

Stakeholder Impact

• The stock sale by a high-ranking officer could potentially create uncertainty among shareholders, although the impact is likely to be minimal given the pre-planned nature of the sale.

Key Dates